

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC PHARMACEUTICAL GROUP LIMITED,
CSPC OUYI PHARMACEUTICAL CO., LTD., AND
CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioners,

v.

IPSEN BIOPHARM LTD.,
Patent Owner.

Case No. IPR2025-00505
Patent No. 11,344,552

**PETITIONER'S UPDATED MANDATORY NOTICES
PURSUANT TO 37 C.F.R. § 42.8(b)**

Pursuant to 37 C.F.R. § 42.8, CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjuro Biotherapeutics, Inc., (collectively “Petitioner”), hereby submits the following updated mandatory notices in connection with Petitioners’ Petition for *Inter Partes* review of U.S. Patent No. 11,344,552, Case No. IPR2025-00505, which identifies a new party and a new related matter pursuant to 37 C.F.R. §§ 42.8(b)(1)-(2).

A. Real Party-in-Interest Under 37 C.F.R. § 42.8(b)(1)

The real parties-in-interest are: CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjuro Biotherapeutics, Inc.

Petitioner disagrees with the allegations made by Patent Owner Ipsen Biopharm Ltd. in its Patent Owner Preliminary Response that Cipla USA Inc. (“Cipla”) is a real party-in-interest. (*See* Paper 9 at 15-16.) However, and out of an abundance of caution, Petitioner identifies Cipla pursuant to Section 42.8(b)(1) and states that on May 14, 2025, Conjuro and Cipla entered into a licensing agreement that granted Cipla an exclusive license to market and distribute certain products, which does not currently include a first-line treatment as claimed by the ‘552 Patent.

B. Related Matters Under 37 C.F.R. § 42.8(b)(2)

U.S. Patent Application No. 19/188,672 (“the ‘672 App.”) claims priority to U.S. Patent Application No. 15/809,815, which issued as U.S. Patent No. 11,344,552. The ‘672 App. was filed on April 24, 2025 and remains pending.

C. Lead and Backup Counsel, Under 37 C.F.R. § 42.8(b)(3)

Lead Counsel	Backup Counsel
Luke Toft (Reg. No. 75,311) ltoft@foxrothschild.com Fox Rothschild LLP 33 South Sixth Street, Suite 3600 Minneapolis, MN 55402 Tel: (612) 607-7336 Fax: (612) 607-7100	Joe Chen (Reg. No. 70,066) joechen@foxrothschild.com Fox Rothschild LLP 212 Carnegie Center, Suite 400 Princeton, NJ 08540 Tel: (609) 844-3024 Fax: (609) 896-1469
	Howard S. Suh (pro hac vice to be filed) hsuh@foxrothschild.com Fox Rothschild LLP 101 Park Avenue, 17th Floor New York, NY 10178 Tel: (212) 878-7914 Fax: (212) 692-0940

D. Service Information

Petitioner continues to consent to electronic service to the e-mail addresses above for lead and backup counsel with a copy to ipdocket@foxrothschild.com (referencing Attorney Docket No. 340008.00021).

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that on July 18, 2025 the foregoing Mandatory Notices from Patent Owner were served via email on the following counsel of record for the Patent Owner:

jimglass@quinnemanuel.com
michaellabas@quinnemanuel.com
anguschen@quinnemanuel.com
quincylu@quinnemanuel.com
elizabethmurphy@quinnemanuel.com
rossmisskelley@quinnemanuel.com

Dated: July 18, 2025

By: /Lukas Toft/
Lukas Toft
Reg. No. 75,311
Counsel for Petitioners